Loading...
•
Sep 30, 2025
BioNano Q3 2025 Earnings Report
Bionano reported a narrower net loss for Q3 2025 alongside a 21% increase in revenue year-over-year, supported by higher instrument and consumables sales.
Key Takeaways
Bionano delivered improved results in Q3 2025, with revenue growth and significantly lower operating expenses contributing to a reduced net loss. The company also reported higher flowcell sales and an increase in installed systems, indicating ongoing adoption of its optical genome mapping platform.
Revenue reached $7.37 million, up from $6.07 million in Q3 2024.
Net loss narrowed to $8.5 million, a significant improvement from $44.2 million in the prior year quarter.
Operating expenses dropped 66% year-over-year, demonstrating strong cost discipline.
Flowcell shipments increased 7% YoY to 8,390, while the installed base rose to 384 systems.
Revenue by Segment
Forward Guidance
Bionano reiterated its full-year revenue guidance and initiated Q4 expectations, projecting modest sequential growth and more than 25 OGM system installations for the year.
Positive Outlook
- Q4 2025 revenue guidance set between $7.5M and $7.9M
- Full-year 2025 revenue outlook remains $26M to $30M
- Instrument installations expected to exceed 25 for FY25
- New CMS CPT code determination for OGM supports reimbursement pathway
- Strong publication momentum reinforces clinical and research utility of OGM
Challenges Ahead
- Company remains unprofitable with negative operating income
- Cash and cash equivalents dropped to $3.1 million
- Dependency on additional financing to sustain operations
- Macroeconomic conditions and global conflicts could pressure growth
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...